A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis

Abstract An increased incidence of narcolepsy type 1 (NT1) was observed in Scandinavia following the 2009–2010 influenza Pandemrix vaccination. The association between NT1 and HLA-DQB1*06:02:01 supported the view of the vaccine as an etiological agent. A/H1N1 hemagglutinin (HA) is the main antigenic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander Lind, Ilaria Marzinotto, Cristina Brigatti, Anita Ramelius, Lorenzo Piemonti, Vito Lampasona
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c358f025cd74411b88b17b1ed5fac4f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c358f025cd74411b88b17b1ed5fac4f1
record_format	dspace
spelling	oai:doaj.org-article:c358f025cd74411b88b17b1ed5fac4f12021-12-02T14:21:59ZA/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis10.1038/s41598-021-83543-z2045-2322https://doaj.org/article/c358f025cd74411b88b17b1ed5fac4f12021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83543-zhttps://doaj.org/toc/2045-2322Abstract An increased incidence of narcolepsy type 1 (NT1) was observed in Scandinavia following the 2009–2010 influenza Pandemrix vaccination. The association between NT1 and HLA-DQB106:02:01 supported the view of the vaccine as an etiological agent. A/H1N1 hemagglutinin (HA) is the main antigenic determinant of the host neutralization antibody response. Using two different immunoassays, the Luciferase Immunoprecipitation System (LIPS) and Radiobinding Assay (RBA), we investigated HA antibody levels and affinity in an exploratory and in a confirmatory cohort of Swedish NT1 patients and healthy controls vaccinated with Pandemrix. HA antibodies were increased in NT1 patients compared to controls in the exploratory (LIPS p = 0.0295, RBA p = 0.0369) but not in the confirmatory cohort (LIPS p = 0.55, RBA p = 0.625). HA antibody affinity, assessed by competition with Pandemrix vaccine, was comparable between patients and controls (LIPS: 48 vs. 39 ng/ml, p = 0.81; RBA: 472 vs. 491 ng/ml, p = 0.65). The LIPS assay also detected higher HA antibody titres as associated with HLA-DQB106:02:01 (p = 0.02). Our study shows that following Pandemrix vaccination, HA antibodies levels and affinity were comparable NT1 patients and controls and suggests that HA antibodies are unlikely to play a role in NT1 pathogenesis.Alexander LindIlaria MarzinottoCristina BrigattiAnita RameliusLorenzo PiemontiVito LampasonaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alexander Lind Ilaria Marzinotto Cristina Brigatti Anita Ramelius Lorenzo Piemonti Vito Lampasona A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis
description	Abstract An increased incidence of narcolepsy type 1 (NT1) was observed in Scandinavia following the 2009–2010 influenza Pandemrix vaccination. The association between NT1 and HLA-DQB106:02:01 supported the view of the vaccine as an etiological agent. A/H1N1 hemagglutinin (HA) is the main antigenic determinant of the host neutralization antibody response. Using two different immunoassays, the Luciferase Immunoprecipitation System (LIPS) and Radiobinding Assay (RBA), we investigated HA antibody levels and affinity in an exploratory and in a confirmatory cohort of Swedish NT1 patients and healthy controls vaccinated with Pandemrix. HA antibodies were increased in NT1 patients compared to controls in the exploratory (LIPS p = 0.0295, RBA p = 0.0369) but not in the confirmatory cohort (LIPS p = 0.55, RBA p = 0.625). HA antibody affinity, assessed by competition with Pandemrix vaccine, was comparable between patients and controls (LIPS: 48 vs. 39 ng/ml, p = 0.81; RBA: 472 vs. 491 ng/ml, p = 0.65). The LIPS assay also detected higher HA antibody titres as associated with HLA-DQB106:02:01 (p = 0.02). Our study shows that following Pandemrix vaccination, HA antibodies levels and affinity were comparable NT1 patients and controls and suggests that HA antibodies are unlikely to play a role in NT1 pathogenesis.
format	article
author	Alexander Lind Ilaria Marzinotto Cristina Brigatti Anita Ramelius Lorenzo Piemonti Vito Lampasona
author_facet	Alexander Lind Ilaria Marzinotto Cristina Brigatti Anita Ramelius Lorenzo Piemonti Vito Lampasona
author_sort	Alexander Lind
title	A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis
title_short	A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis
title_full	A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis
title_fullStr	A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis
title_full_unstemmed	A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis
title_sort	a/h1n1 hemagglutinin antibodies show comparable affinity in vaccine-related narcolepsy type 1 and control and are unlikely to contribute to pathogenesis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c358f025cd74411b88b17b1ed5fac4f1
work_keys_str_mv	AT alexanderlind ah1n1hemagglutininantibodiesshowcomparableaffinityinvaccinerelatednarcolepsytype1andcontrolandareunlikelytocontributetopathogenesis AT ilariamarzinotto ah1n1hemagglutininantibodiesshowcomparableaffinityinvaccinerelatednarcolepsytype1andcontrolandareunlikelytocontributetopathogenesis AT cristinabrigatti ah1n1hemagglutininantibodiesshowcomparableaffinityinvaccinerelatednarcolepsytype1andcontrolandareunlikelytocontributetopathogenesis AT anitaramelius ah1n1hemagglutininantibodiesshowcomparableaffinityinvaccinerelatednarcolepsytype1andcontrolandareunlikelytocontributetopathogenesis AT lorenzopiemonti ah1n1hemagglutininantibodiesshowcomparableaffinityinvaccinerelatednarcolepsytype1andcontrolandareunlikelytocontributetopathogenesis AT vitolampasona ah1n1hemagglutininantibodiesshowcomparableaffinityinvaccinerelatednarcolepsytype1andcontrolandareunlikelytocontributetopathogenesis
_version_	1718391513805750272

A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis

Ejemplares similares